Period,symbol,NAV,sharesOutstanding,researchDevelopment,effectOfAccountingCharges,incomeBeforeTax,minorityInterest,netIncome,sellingGeneralAdministrative,grossProfit,ebit,operatingIncome,otherOperatingExpenses,interestExpense,extraordinaryItems,nonRecurring,otherItems,incomeTaxExpense,totalRevenue,totalOperatingExpenses,costOfRevenue,totalOtherIncomeExpenseNet,discontinuedOperations,netIncomeFromContinuingOps,netIncomeApplicableToCommonShares,intangibleAssets,capitalSurplus,totalLiab,totalStockholderEquity,totalAssets,commonStock,retainedEarnings,otherLiab,otherAssets,cash,totalCurrentLiabilities,propertyPlantEquipment,totalCurrentAssets,accountsPayable,otherCurrentLiab,changeToLiabilities,totalCashFromFinancingActivities,changeToOperatingActivities,issuanceOfStock,changeInCash,totalCashFromOperatingActivities,depreciation,changeToNetincome,otherCashflowsFromFinancingActivities,WC,language,region,quoteType,triggerable,quoteSourceName,dividendDate,regularMarketChangePercent,regularMarketDayRange,ask,bid,regularMarketPreviousClose,bidSize,askSize,messageBoardId,fullExchangeName,longName,financialCurrency,averageDailyVolume3Month,averageDailyVolume10Day,fiftyTwoWeekLowChange,fiftyTwoWeekLowChangePercent,fiftyTwoWeekRange,fiftyTwoWeekHighChange,fiftyTwoWeekHighChangePercent,fiftyTwoWeekLow,fiftyTwoWeekHigh,earningsTimestamp,earningsTimestampStart,earningsTimestampEnd,currency,marketState,regularMarketPrice,regularMarketTime,regularMarketChange,regularMarketOpen,regularMarketDayHigh,regularMarketDayLow,regularMarketVolume,market,priceHint,exchangeDataDelayedBy,twoHundredDayAverageChangePercent,shortName,exchange,epsTrailingTwelveMonths,epsForward,epsCurrentYear,priceEpsCurrentYear,bookValue,fiftyDayAverage,fiftyDayAverageChange,fiftyDayAverageChangePercent,twoHundredDayAverage,twoHundredDayAverageChange,marketCap,forwardPE,priceToBook,sourceInterval,exchangeTimezoneName,exchangeTimezoneShortName,gmtOffSetMilliseconds,esgPopulated,tradeable,Beta (5Y Monthly),52-Week Change 3,S&P500 52-Week Change 3,52 Week High 3,52 Week Low 3,50-Day Moving Average 3,200-Day Moving Average 3,Avg Vol (3 month) 3,Avg Vol (10 day) 3,Shares Outstanding 5,Implied Shares Outstanding 6,Float,% Held by Insiders 1,% Held by Institutions 1,"Shares Short (Jul 14, 2021) 4","Short Ratio (Jul 14, 2021) 4","Short % of Float (Jul 14, 2021) 4","Short % of Shares Outstanding (Jul 14, 2021) 4","Shares Short (prior month Jun 14, 2021) 4",Forward Annual Dividend Rate 4,Forward Annual Dividend Yield 4,Trailing Annual Dividend Rate 3,Trailing Annual Dividend Yield 3,5 Year Average Dividend Yield 4,Payout Ratio 4,Dividend Date 3,Ex-Dividend Date 4,Last Split Factor 2,Last Split Date 3,Fiscal Year Ends,Most Recent Quarter (mrq),Profit Margin,Operating Margin (ttm),Return on Assets (ttm),Return on Equity (ttm),Revenue (ttm),Revenue Per Share (ttm),Quarterly Revenue Growth (yoy),Gross Profit (ttm),EBITDA,Net Income Avi to Common (ttm),Diluted EPS (ttm),Quarterly Earnings Growth (yoy),Total Cash (mrq),Total Cash Per Share (mrq),Total Debt (mrq),Total Debt/Equity (mrq),Current Ratio (mrq),Book Value Per Share (mrq),Operating Cash Flow (ttm),Levered Free Cash Flow (ttm),index,zip,sector,fullTimeEmployees,longBusinessSummary,city,phone,state,compensationAsOfEpochDate,country,website,maxAge,address1,industry,address2
t0,DFFN,45008295.0,101904000,2916378,,-4643919,,-4643919,1743510,0,-4684335,-4684335,,,,,,0,0,4684335,0,40416,,-4643919,-4643919,8639000.0,164098694.0,2565816.0,53647295.0,56213111.0,101904.0,-110553303.0,443893.0,15580.0,46634977.0,2113104.0,244861.0,47313670.0,952909.0,,-320501.0,33295752.0,-417677.0,33295752.0,28119382.0,-5176370.0,24447.0,181280.0,,45200566.0,en-US,US,EQUITY,True,Nasdaq Real Time Price,1544745600,-0.93204856,0.572 - 0.595,0.5825,0.5858,0.5901,10,12,finmb_8931412,NasdaqCM,Diffusion Pharmaceuticals Inc.,USD,1547121,1442316,0.12459996,0.2708695,0.46 - 1.85,-1.2654,-0.684,0.46,1.85,1620630300,1628512200,1628857800,USD,REGULAR,0.5846,1630504287,-0.0055000186,0.572,0.595,0.572,141340,us_market,4,0,-0.23654023,Diffusion Pharmaceuticals Inc.,NCM,-0.276,-0.19,-0.17,-3.4388232,0.526,0.5477778,0.0368222,0.06722105,0.76572466,-0.18112469,59573076,-3.076842,1.1114067,15,America/New_York,EDT,-14400000,False,False,1.59,,,1.85,0.46,0.5478,0.7657,1.55M,1.44M,101.9M,,101.72M,0.18%,11.45%,1.74M,0.89,1.71%,1.71%,1.01M,,,,,,0.00%,"Dec 13, 2018",,1:15,"Dec 13, 2018","Dec 30, 2020","Mar 30, 2021",0.00%,0.00%,-28.64%,-45.48%,,,,,-17.6M,-18.22M,-0.2760,,46.63M,0.46,120.11k,0.22,22.39,0.53,-15.22M,-9.2M,Value,22902,Healthcare,12,"Diffusion Pharmaceuticals Inc., a biopharmaceutical company, develops novel therapies that enhance the body's ability to deliver oxygen. Its lead product candidate is Trans Sodium Crocetinate that is developed to enhance the diffusion of oxygen to tissues, as well as to treat COVID-19 disease. The company is also developing DFN-529, a phosphoinositide 3-kinase/Akt/mechanistic target of rapamycin pathway inhibitor. Diffusion Pharmaceuticals Inc. was founded in 2001 and is based in Charlottesville, Virginia.",Charlottesville,434 220 0718,VA,1609372800,United States,http://www.diffusionpharma.com,86400,1317 Carlton Avenue,Biotechnology,Suite 200
t-1,DFFN,16175182.0,101904000,2582464,,-4062057,,-4062057,1479669,0,-4087068,-4087068,,,,,,0,0,4087068,0,25011,,-4062057,-4062057,8639000.0,130659550.0,2915369.0,24814182.0,27729551.0,64016.0,-105909384.0,443893.0,15771.0,18515595.0,2435783.0,298360.0,18776420.0,545844.0,35364.0,-251681.0,33295752.0,742393.0,33295752.0,-3394588.0,-3394588.0,24935.0,151822.0,,16340637.0,en-US,US,EQUITY,True,Nasdaq Real Time Price,1544745600,-0.93204856,0.572 - 0.595,0.5825,0.5858,0.5901,10,12,finmb_8931412,NasdaqCM,Diffusion Pharmaceuticals Inc.,USD,1547121,1442316,0.12459996,0.2708695,0.46 - 1.85,-1.2654,-0.684,0.46,1.85,1620630300,1628512200,1628857800,USD,REGULAR,0.5846,1630504287,-0.0055000186,0.572,0.595,0.572,141340,us_market,4,0,-0.23654023,Diffusion Pharmaceuticals Inc.,NCM,-0.276,-0.19,-0.17,-3.4388232,0.526,0.5477778,0.0368222,0.06722105,0.76572466,-0.18112469,59573076,-3.076842,1.1114067,15,America/New_York,EDT,-14400000,False,False,1.59,,,1.85,0.46,0.5478,0.7657,1.55M,1.44M,101.9M,,101.72M,0.18%,11.45%,1.74M,0.89,1.71%,1.71%,1.01M,,,,,,0.00%,"Dec 13, 2018",,1:15,"Dec 13, 2018","Dec 30, 2020","Mar 30, 2021",0.00%,0.00%,-28.64%,-45.48%,,,,,-17.6M,-18.22M,-0.2760,,46.63M,0.46,120.11k,0.22,22.39,0.53,-15.22M,-9.2M,Value,22902,Healthcare,12,"Diffusion Pharmaceuticals Inc., a biopharmaceutical company, develops novel therapies that enhance the body's ability to deliver oxygen. Its lead product candidate is Trans Sodium Crocetinate that is developed to enhance the diffusion of oxygen to tissues, as well as to treat COVID-19 disease. The company is also developing DFN-529, a phosphoinositide 3-kinase/Akt/mechanistic target of rapamycin pathway inhibitor. Diffusion Pharmaceuticals Inc. was founded in 2001 and is based in Charlottesville, Virginia.",Charlottesville,434 220 0718,VA,1609372800,United States,http://www.diffusionpharma.com,86400,1317 Carlton Avenue,Biotechnology,Suite 200
t-2,DFFN,20085417.0,101904000,3137553,,-5244887,,-4439211,2112375,0,-5274120,-5274120,,,,,,-805676,0,5274120,0,29233,,-4439211,-4439211,8639000.0,130507728.0,3192556.0,28724417.0,31916973.0,64016.0,-101847327.0,443893.0,252057.0,21910183.0,2686948.0,348801.0,22677115.0,1411717.0,,1050872.0,-141400.0,380334.0,7500.0,-3651416.0,-3510016.0,24192.0,-526203.0,-148900.0,19990167.0,en-US,US,EQUITY,True,Nasdaq Real Time Price,1544745600,-0.93204856,0.572 - 0.595,0.5825,0.5858,0.5901,10,12,finmb_8931412,NasdaqCM,Diffusion Pharmaceuticals Inc.,USD,1547121,1442316,0.12459996,0.2708695,0.46 - 1.85,-1.2654,-0.684,0.46,1.85,1620630300,1628512200,1628857800,USD,REGULAR,0.5846,1630504287,-0.0055000186,0.572,0.595,0.572,141340,us_market,4,0,-0.23654023,Diffusion Pharmaceuticals Inc.,NCM,-0.276,-0.19,-0.17,-3.4388232,0.526,0.5477778,0.0368222,0.06722105,0.76572466,-0.18112469,59573076,-3.076842,1.1114067,15,America/New_York,EDT,-14400000,False,False,1.59,,,1.85,0.46,0.5478,0.7657,1.55M,1.44M,101.9M,,101.72M,0.18%,11.45%,1.74M,0.89,1.71%,1.71%,1.01M,,,,,,0.00%,"Dec 13, 2018",,1:15,"Dec 13, 2018","Dec 30, 2020","Mar 30, 2021",0.00%,0.00%,-28.64%,-45.48%,,,,,-17.6M,-18.22M,-0.2760,,46.63M,0.46,120.11k,0.22,22.39,0.53,-15.22M,-9.2M,Value,22902,Healthcare,12,"Diffusion Pharmaceuticals Inc., a biopharmaceutical company, develops novel therapies that enhance the body's ability to deliver oxygen. Its lead product candidate is Trans Sodium Crocetinate that is developed to enhance the diffusion of oxygen to tissues, as well as to treat COVID-19 disease. The company is also developing DFN-529, a phosphoinositide 3-kinase/Akt/mechanistic target of rapamycin pathway inhibitor. Diffusion Pharmaceuticals Inc. was founded in 2001 and is based in Charlottesville, Virginia.",Charlottesville,434 220 0718,VA,1609372800,United States,http://www.diffusionpharma.com,86400,1317 Carlton Avenue,Biotechnology,Suite 200
t-3,DFFN,24237655.0,101904000,2173183,,-3632548,,-3125223,1458257,0,-3658461,-3658461,,,,,,-507325,0,3658461,0,25913,,-3125223,-5075601,8639000.0,130220772.0,3116471.0,32876655.0,35993126.0,63999.0,-97408116.0,1249569.0,252149.0,25561599.0,1781831.0,393204.0,26708773.0,1354948.0,,606900.0,17877082.0,-258528.0,18472278.0,14733371.0,-3143711.0,27021.0,-393881.0,-595196.0,24926942.0,en-US,US,EQUITY,True,Nasdaq Real Time Price,1544745600,-0.93204856,0.572 - 0.595,0.5825,0.5858,0.5901,10,12,finmb_8931412,NasdaqCM,Diffusion Pharmaceuticals Inc.,USD,1547121,1442316,0.12459996,0.2708695,0.46 - 1.85,-1.2654,-0.684,0.46,1.85,1620630300,1628512200,1628857800,USD,REGULAR,0.5846,1630504287,-0.0055000186,0.572,0.595,0.572,141340,us_market,4,0,-0.23654023,Diffusion Pharmaceuticals Inc.,NCM,-0.276,-0.19,-0.17,-3.4388232,0.526,0.5477778,0.0368222,0.06722105,0.76572466,-0.18112469,59573076,-3.076842,1.1114067,15,America/New_York,EDT,-14400000,False,False,1.59,,,1.85,0.46,0.5478,0.7657,1.55M,1.44M,101.9M,,101.72M,0.18%,11.45%,1.74M,0.89,1.71%,1.71%,1.01M,,,,,,0.00%,"Dec 13, 2018",,1:15,"Dec 13, 2018","Dec 30, 2020","Mar 30, 2021",0.00%,0.00%,-28.64%,-45.48%,,,,,-17.6M,-18.22M,-0.2760,,46.63M,0.46,120.11k,0.22,22.39,0.53,-15.22M,-9.2M,Value,22902,Healthcare,12,"Diffusion Pharmaceuticals Inc., a biopharmaceutical company, develops novel therapies that enhance the body's ability to deliver oxygen. Its lead product candidate is Trans Sodium Crocetinate that is developed to enhance the diffusion of oxygen to tissues, as well as to treat COVID-19 disease. The company is also developing DFN-529, a phosphoinositide 3-kinase/Akt/mechanistic target of rapamycin pathway inhibitor. Diffusion Pharmaceuticals Inc. was founded in 2001 and is based in Charlottesville, Virginia.",Charlottesville,434 220 0718,VA,1609372800,United States,http://www.diffusionpharma.com,86400,1317 Carlton Avenue,Biotechnology,Suite 200
